South Korea
· Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 292.80 billion. The enterprise value is 285.40 billion.
| Market Cap | 292.80B |
| Enterprise Value | 285.40B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio Plus has 57.19 million shares outstanding. The number of shares has increased by 1.46% in one year.
| Shares Outstanding | 57.19M |
| Shares Change (YoY) | +1.46% |
| Shares Change (QoQ) | +1.53% |
| Owned by Insiders (%) | 33.37% |
| Owned by Institutions (%) | 6.41% |
| Float | 37.94M |
Valuation Ratios
The trailing PE ratio is 14.85.
| PE Ratio | 14.85 |
| Forward PE | n/a |
| PS Ratio | 5.37 |
| PB Ratio | 2.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.11, with an EV/FCF ratio of -10.34.
| EV / Earnings | 14.26 |
| EV / Sales | 5.23 |
| EV / EBITDA | 13.11 |
| EV / EBIT | 15.11 |
| EV / FCF | -10.34 |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 3.58.
| Current Ratio | 2.58 |
| Quick Ratio | 2.05 |
| Debt / Equity | 3.58 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | -0.19 |
| Interest Coverage | 125.67 |
Financial Efficiency
Return on equity (ROE) is 16.38% and return on invested capital (ROIC) is 8.20%.
| Return on Equity (ROE) | 16.38% |
| Return on Assets (ROA) | 7.05% |
| Return on Capital (ROIC) | 8.20% |
| Revenue Per Employee | 634.67M |
| Profits Per Employee | 232.71M |
| Employee Count | 86 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.19% |
| 50-Day Moving Average | 5,971.40 |
| 200-Day Moving Average | 6,272.98 |
| Relative Strength Index (RSI) | 30.93 |
| Average Volume (20 Days) | 402,577 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 54.58 billion and earned 20.01 billion in profits. Earnings per share was 344.76.
| Revenue | 54.58B |
| Gross Profit | 32.15B |
| Operating Income | 18.89B |
| Pretax Income | 26.42B |
| Net Income | 20.01B |
| EBITDA | 21.77B |
| EBIT | 18.89B |
| Earnings Per Share (EPS) | 344.76 |
Balance Sheet
The company has 31.49 billion in cash and 5.33 billion in debt, giving a net cash position of 26.16 billion or 457.46 per share.
| Cash & Cash Equivalents | 31.49B |
| Total Debt | 5.33B |
| Net Cash | 26.16B |
| Net Cash Per Share | 457.46 |
| Equity (Book Value) | 149.10B |
| Book Value Per Share | 2,289.32 |
| Working Capital | 35.24B |
Cash Flow
In the last 12 months, operating cash flow was 29.69 billion and capital expenditures -57.29 billion, giving a free cash flow of -27.60 billion.
| Operating Cash Flow | 29.69B |
| Capital Expenditures | -57.29B |
| Free Cash Flow | -27.60B |
| FCF Per Share | -482.64 |
Margins
Gross margin is 58.90%, with operating and profit margins of 34.61% and 36.67%.
| Gross Margin | 58.90% |
| Operating Margin | 34.61% |
| Pretax Margin | 48.41% |
| Profit Margin | 36.67% |
| EBITDA Margin | 39.88% |
| EBIT Margin | 34.61% |
| FCF Margin | -50.57% |
Dividends & Yields
This stock pays an annual dividend of 70.00, which amounts to a dividend yield of 1.40%.
| Dividend Per Share | 70.00 |
| Dividend Yield | 1.40% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.97% |
| Buyback Yield | -1.46% |
| Shareholder Yield | -0.06% |
| Earnings Yield | 6.73% |
| FCF Yield | -9.43% |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |